Cancer Family
Endocrine Neoplasm
CI-CAN-00000015Explore in graph →
Non-malignant764 active trials16 approved drugs64 evidence items
- NCIt
- C3010
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000015Explore in graph →
Clinical trials
2,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03361384 | Alcohol and Implicit Process in Sexual Risk Behavior in MSM | completed | Phase 1 | 260 | Syracuse UniversityOTHER | 1 | Jul 23, 2021 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| A Study of AK-01 (LY3295668) in Solid Tumors |
| completed |
| Phase 1 / Phase 2 |
| 13 |
| Eli Lilly and CompanyINDUSTRY |
| 1 |
| Jul 2, 2021 |
| clinicaltrials |
| NCT01840579 | Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | completed | Phase 1 | 57 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT02701400 | Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer | completed | Phase 2 | 18 | Emory UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04557072 | Selective Versus Nonselective Alpha-blockade Prior to Pheochromocytoma Resection - Systematic Review and Meta-analysis | completed | — | 1,344 | Jagiellonian UniversityOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03189953 | 68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH(GLP-1-AHH) | completed | Phase 1 / Phase 2 | 56 | Radboud University Medical CenterOTHER | 0 | Jun 16, 2021 | clinicaltrials |
| NCT02810600 | Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors(PET/Ga68) | completed | — | 2,120 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT00511862 | TheraSphere for the Treatment of Liver Metastases | completed | Phase 2 | 151 | Boston Scientific CorporationINDUSTRY | 1 | May 13, 2021 | clinicaltrials |
| NCT04840771 | Predictive OCTA Biomarkers After Endoscopic Endonasal Pituitary Surgery | completed | — | 8 | Federico II UniversityOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02973204 | Circulating Tumor Cells and Tumor DNA in HCC and NET | completed | — | 167 | University of AarhusOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT04831463 | The Effect of the Program on the Health Perceptions and Responsibilities of Immigrant Men on Utiling Healthcare Services(IHAP) | completed | N/A | 100 | Ondokuz Mayıs UniversityOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT01563354 | 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial(LUNA) | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 9 | Apr 2, 2021 | clinicaltrials |
| NCT02593019 | Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients | completed | Phase 2 | 24 | Samsung Medical CenterOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT03325816 | Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02939651 | A Study of Pembrolizumab in Patients With Neuroendocrine Tumors | completed | Phase 2 | 21 | Fox Chase Cancer CenterOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT04780737 | Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis | completed | — | 230 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT01327612 | Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) | completed | Phase 2 | 12 | AmgenINDUSTRY | 3 | Feb 21, 2021 | clinicaltrials |
| NCT03009682 | Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B) | completed | Phase 2 | 15 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT03428607 | Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2] | completed | Phase 2 | 26 | Samsung Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT04753229 | Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia(TNE-P-Ki) | completed | — | 50 | Institut Paoli-CalmettesOTHER | 0 | Feb 18, 2021 | clinicaltrials |
| NCT01470248 | Study of Arsenic Trioxide in Small Cell Lung Cancer | completed | Phase 2 | 20 | Emory UniversityOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT03072160 | Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03059667 | Immunotherapy as Second-line in Patient With Small Cell Lung Cancer | completed | Phase 2 | 73 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT04546386 | Long-term Follow up for Retinal Vascular Changes After Endoscopic Endonasal Pituitary Surgery. | completed | — | 14 | Federico II UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04207762 | 18F-AmBF3-TATE PET/CT for Imaging NET Patients | completed | — | 10 | British Columbia Cancer AgencyOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01967576 | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2021 | clinicaltrials |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | completed | Phase 1 / Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT00514046 | Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Dec 22, 2020 | clinicaltrials |
| NCT00446082 | Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease | completed | Phase 1 | 85 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 21, 2020 | clinicaltrials |
| NCT00466466 | Safety of RAD001 in Combination With Cisplatin and Etoposide in Lung Cancer Patients | completed | Phase 1 | 20 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 21, 2020 | clinicaltrials |
| NCT01263353 | Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs(COOPERATE-1) | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT01364415 | Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) | completed | Phase 1 | 29 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT03098030 | Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 483 | United TherapeuticsINDUSTRY | 23 | Dec 9, 2020 | clinicaltrials |
| NCT03547804 | A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer(MK 01) | completed | Phase 2 | 31 | The First Hospital of Jilin UniversityOTHER | 1 | Dec 1, 2020 | clinicaltrials |
| NCT00501449 | Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes | completed | — | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT00326469 | Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours | completed | Phase 2 | 30 | IpsenINDUSTRY | 1 | Nov 5, 2020 | clinicaltrials |
| NCT00415363 | Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy | completed | Phase 2 | 109 | Eli Lilly and CompanyINDUSTRY | 5 | Nov 5, 2020 | clinicaltrials |
| NCT02853422 | Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours(QUALINETS) | completed | — | 199 | IpsenINDUSTRY | 2 | Nov 5, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04122911 | Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas(TENEC) | completed | Phase 2 | 25 | National Cancer Institute, NaplesOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04594720 | Circulating Biomarkers to Identify Thyroid Cancer | completed | — | 100 | Chang Gung Memorial HospitalOTHER | 1 | Oct 20, 2020 | clinicaltrials |
| NCT02698410 | Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.(ATLANT) | completed | Phase 2 | 40 | IpsenINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 23, 2021source: clinicaltrials